DeepMed Research

Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma

Phase 4

Completed

Conditions: Metastatic Renal Cell Carcinoma
Metastatic Melanoma

Interventions: Drug: Aldesleukin

First Posted Date: 2006-12-22

Last Posted Date: 2021-06-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 26

Registration Number: NCT00414765

Locations: 🇺🇸
James Graham Brown Cancer Center, Louisville, Kentucky, United States
🇺🇸
USC/Kenneth Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
University of Colorado Cancer Center, Aurora, Colorado, United States

and more 1 locations

Efficacy, Safety and Tolerability of Everolimus in Preventing End-stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease

Phase 4

Completed

Conditions: Autosomal Dominant Polycystic Kidney Disease

Interventions: Drug: Everolimus
Drug: Placebo

First Posted Date: 2006-12-21

Last Posted Date: 2015-01-14

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 431

Registration Number: NCT00414440

Locations: 🇩🇪
Novartis Investigative Site, Würzburg, Germany

Oral Nilotinib in Adults With Chronic Myeloid Leukemia (CML) in Blast Crisis Who Are Imatinib Resistant or Intolerant

Conditions: Chronic Myelogenous Leukemia

First Posted Date: 2006-12-19

Last Posted Date: 2011-07-13

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT00413270

Locations: 🇨🇦
Novartis Investigative Site, Quebec, Canada

Efficacy/Safety of Valsartan Plus Amlodipine and Valsartan Alone in Patients With Hypertension

Phase 3

Completed

Conditions: Hypertension

Interventions: Drug: Valsartan 160 mg
Drug: Valsartan/amlodipine 80/5 mg
Drug: Valsartan 80 mg

First Posted Date: 2006-12-19

Last Posted Date: 2011-04-28

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 1134

Registration Number: NCT00413413

Locations: 🇨🇳
Department of cardiology, Ruijin hospital;, Shanghai, China
🇨🇳
Second Hospital of Hebei University of Medical Sciences, Shijiazhuang, China
🇨🇳
Beijing General Hospital of Beijing Military Region, Beijing, China

and more 16 locations

Efficacy and Safety of Patupilone in Patients With Advanced Solid Tumors in Japan

Phase 1

Completed

Conditions: Tumors

Interventions: Drug: Patupilone

First Posted Date: 2006-12-18

Last Posted Date: 2010-05-31

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 15

Registration Number: NCT00412789

Locations: 🇯🇵
Novartis Investigative Site, Tokyo, Japan

Viral Kinetics Study of Telbivudine and Entecavir in Adults With Chronic Hepatitis B

Phase 3

Completed

Conditions: Chronic Hepatitis B
Hepatitis B

Interventions: Drug: Telbivudine
Drug: Entecavir

First Posted Date: 2006-12-18

Last Posted Date: 2015-03-13

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 44

Registration Number: NCT00412529

Locations: 🇰🇷
Yeungnam University Medical Center, Daegu, Korea, Republic of
🇰🇷
Gachon Univ. Gil Medical Center Hospital, Incheon, Korea, Republic of
🇰🇷
Asan Medical Center, Seoul, Korea, Republic of

and more 5 locations

Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor

Phase 3

Completed

Conditions: Carcinoid Tumor
Malignant Carcinoid Syndrome

Interventions: Drug: Octreotide
Drug: Placebo
Drug: Everolimus

First Posted Date: 2006-12-15

Last Posted Date: 2014-11-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 429

Registration Number: NCT00412061

Locations: 🇺🇸
New York Oncology Hematology, P.C. Dept. of New York Oncology. PC, Albany, New York, United States
🇺🇸
Pacific Cancer Medical Center, Inc., Anaheim, California, United States
🇺🇸
Cancer Centers of Connecticut Southington Location, Southington, Connecticut, United States

and more 36 locations

Safety and Tolerability Study in Patients With Mild to Moderate Alzheimer's Disease (AD)

Phase 1

Completed

Conditions: Alzheimer's Disease

Interventions: Biological: CAD106
Drug: Placebo

First Posted Date: 2006-12-14

Last Posted Date: 2013-03-29

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 58

Registration Number: NCT00411580

Locations: 🇸🇪
Novartis Investigative Site, Stockholm, Sweden

Efficacy and Safety of Patupilone in Men (≥18 Years) With Metastatic Hormone Refractory Prostate Cancer

Phase 2

Completed

Conditions: Metastatic Hormone Refractory Prostate Cancer

Interventions: Drug: Patupilone
Drug: prednisone
Drug: docetaxel

First Posted Date: 2006-12-14

Last Posted Date: 2020-12-17

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 185

Registration Number: NCT00411528

Locations: 🇺🇸
University of Colorado Dept. of Univ. of Colorado, Aurora, Colorado, United States
🇺🇸
University of California San Diego Dept of Moores Cancer Center, La Jolla, California, United States
🇺🇸
Norwalk Hospital, Norwalk, Connecticut, United States

and more 9 locations

RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib

Phase 3

Completed

Conditions: Metastatic Renal Cell Carcinoma

Interventions: Drug: Placebo
Drug: RAD001

First Posted Date: 2006-12-12

Last Posted Date: 2013-01-15

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 416

Registration Number: NCT00410124

Locations: 🇪🇸
Novartis Investigative Site, Valencia, Spain

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy